Klug entscheiden in der Rheumatologie

 

Literaturnachweise

  1. Zhang W, Doherty M, Pascual E, et al.: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301–11. 
  2. Zhang W, Doherty M, Bardin T, et al.: European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563–70. 
  3. Landewe RBM, Günther KP, Lukas C, et al.: EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. Ann Rheum Dis 2010; 69: 12–9. 
  4. Neogi T, Jansen T L Th A, Dalbeth N, et al.: 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol 2015; 67: 2557–68. 
  5. Mukhtyar C, Guillevin L, Cid MC, et al.: European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318–23. 
  6. Dougados M, Soubrier M, Antunez A, et al.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73: 62–8. 
  7. van Assen Set al EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414–22. 
  8. Goldacker S, Gause AM, Warnatz K: Kommission Pharmakotherapie der DGRh. Impfung bei erwachsenen Patienten mit chronisch entzündlichen rheumatischen Erkrankungen Z Rheumatol 2013; 72: 690–704. dgrh.de/fileadmin/media/ Praxis___Klinik/Therapie-Empfehlungen/ impfempfehlungen_dgrh_pharmako_ kommission_2013_lang.pdf 
  9. www.rki.de/DE/Content/Kommissionen/ STIKO/Empfehlungen/Impfempfehlungen_ node.html;jsessionid=02B30769BEA061 CA378D98E106C8F187.2_cid390; www. rki.de/DE/Content/Kommissionen/STIKO/ Empfehlungen/Aktuelles/Impfkalender. pdf?__blob=publicationFile 
  10. Pieringer H, et al.: Rheumatoid arthritis is an independent risk factor for an increased augmentation index regardless of the coexistence of traditional cardiovascular risk factors. Semin Arthritis Rheum 2012; 42: 17–22. 
  11. Benvenuti F, et al.: Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythemsosis: a literature review. Expert Opin Drug Saf 2015; 14: 1373–85. 
  12. Morgan MD, et al.: Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009; 60: 3493–500. 
  13. Semb AG, et al.: Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Ann Rheum Dis 2014; 73: 1284–8. 
  14. Nationale Versorgungsleitlinie (NVL) Kreuzschmerz, Kurzfassung, Version 1.2. 
  15. Auwarter PG, Bakken JS, Dattwyler RS, et al.: Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis 2011; 11: 713–9. 
  16. Stanek G, Fingerle V, Hunfeld KP, et al.: Lyme borreliosis: clinical case definitions for diagnosis and management in Europe (European Union Concerted Action on LB). Clin Microbiol Infect 2011; 17: 69–79. 
  17. Sigal LH: Musculoskeletal features of Lyme disease: understanding the pathogenesis of clinical findings helps make appropriate therapeutic choices. J Clin Rheumatol 2011; 17: 256–65. 
  18. Feder HM, Johnson BJB, O’Connell S, et al.: A critical appraisal of „Chronic Lyme Disease“. N Engl JMed 2007; 357: 1422–30. 
  19. Listing J, Gerhold K, Zink A: The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52: 53–61. 
  20. Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG: Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873–8. 
  21. 21. Dixon WG, Abrahamowicz M, Beauchamp ME, et al.: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71: 1128–33. 
  22. Hensor EMA, Emery P, Bingham SJ, Conaghan PG and the YEAR Consortium: Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? Rheumatology 2010, 49: 1521–9. 
  23. de Vries MK, van Eijk IC, van der Horst- Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ: Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009, 61: 1484–90. 
  24. Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmström G, Larsson PT; Psoriatic Arthritis Group of the Society for Rheumatology: The Swedish early psoriatic arthritis register – 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008; 35: 668–73. 
  25. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797–808. 
  26. Hayashi N, et al.: Prevalence of diseasespecific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 2008; 18: 153–60. 
  27. Maillefert JF, et al.: Prevalence of ANCA in a hospitalized elderly French population. Clin Exp Rheumatol 1997; 15: 603–7. 
  28. Shi W, et al.: Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231–4.

Wir verwenden Cookies auf Ihrem Browser, um die Funktionalität unserer Webseite zu optimieren und den Besuchern personalisierte Werbung anbieten zu können. Bitte bestätigen Sie die Auswahl der Cookies um direkt zu der Webseite zu gelangen. Weitere Informationen finden Sie unter Datenschutz. Dort können Sie auch jederzeit Ihre Cookie-Einstellungen ändern.

Infos
Infos
Mehr Info